AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1093427 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection into the buttock of 10 mg diazepam
Number of subjects: 1
Study 1093427 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral and thigh routes of administration
Number of subjects: 1
Study 31704126 — intervention group
Group type: EXPERIMENTAL
Intervention: Early pacifier use recommendation
Number of subjects: 239
Study 31704126 — intervention group
Group type: COMPARATOR
Intervention: Avoid pacifier use during the first two weeks
Number of subjects: 239
Study 30928344 — intervention group
Group type: EXPERIMENTAL
Intervention: PALS
Number of subjects: 104
Study 30928344 — intervention group
Group type: COMPARATOR
Intervention: WebMD
Number of subjects: 104
Study 27992949 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype-guided dosing for phenprocoumon in younger patients (< 75 years)
Number of subjects: 142
Study 27992949 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype-guided dosing for phenprocoumon in older patients (≥ 75 years)
Number of subjects: 142
Study 27992949 — intervention group
Group type: EXPERIMENTAL
Intervention: Acenocoumarol users with genotype-guided dosing
Number of subjects: 142
Study 27992949 — intervention group
Group type: COMPARATOR
Intervention: Control group for younger patients (< 75 years)
Number of subjects: 142
Study 27992949 — intervention group
Group type: COMPARATOR
Intervention: Control group for older patients (≥ 75 years)
Number of subjects: 142
Study 25971907 — intervention group
Group type: EXPERIMENTAL
Intervention: Obatoclax (20 mg/m2) in combination with fludarabine and rituximab (FR)
Number of subjects: 13
Study 23073215 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (E)
Number of subjects: 23
Study 23073215 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (R)
Number of subjects: 23
Study 21515995 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospice Smart Patient Service (face-to-face or phone) at least once a week for 5 months
Number of subjects: 0
Study 21515995 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 17658633 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan (62.5 mg b.i.d. for 4 weeks, then 125 mg b.i.d.)
Number of subjects: 37
Study 17658633 — intervention group
Group type: COMPARATOR
Intervention: Placebo (ex-placebo group)
Number of subjects: 37
Study 17658633 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (ex-bosentan and ex-placebo)
Number of subjects: 37
Study 17658633 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 37
Study 17053955 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg daily for 8 weeks
Number of subjects: 18
Study 17053955 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 18
Study 17053955 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine and Placebo
Number of subjects: 18
Study 17053955 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 18
Study 14689888 — intervention group
Group type: EXPERIMENTAL
Intervention: DBTC catheter (transurethral perfusion and drainage with antibiotics)
Number of subjects: 103
Study 14689888 — intervention group
Group type: COMPARATOR
Intervention: Intravenous antibiotics
Number of subjects: 103
Study 14689888 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (transurethral irrigation)
Number of subjects: 103
Study 10530851 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy shock waves
Number of subjects: 195
Study 10530851 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy shock waves (one session)
Number of subjects: 195
Study 10530851 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy shock waves (two sessions)
Number of subjects: 195
Study 10530851 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 195
Study 8742456 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia subjects
Number of subjects: 51
Study 8742456 — intervention group
Group type: COMPARATOR
Intervention: Unaffected individuals
Number of subjects: 51
Study 8742456 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia-related illness subjects or obligate carriers
Number of subjects: 51
Study 2024959 — intervention group
Group type: EXPERIMENTAL
Intervention: GR69153
Number of subjects: 0
Study 6118521 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuclear magnetic resonance (NMR) imaging
Number of subjects: 10
Study 6118521 — intervention group
Group type: COMPARATOR
Intervention: Cranial X-ray computed tomography (CT)
Number of subjects: 10
Study 6143042 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated cold‐adapted reassortant influenza virus vaccine (10(7.5) TCID50, intranasally)
Number of subjects: 81
Study 6143042 — intervention group
Group type: COMPARATOR
Intervention: Inactivated vaccine (administered intramuscularly)
Number of subjects: 81
Study 6143042 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated cold‐adapted reassortant influenza virus vaccine (10(7.5) TCID50)
Number of subjects: 81
Study 6143042 — intervention group
Group type: COMPARATOR
Intervention: Inactivated vaccine
Number of subjects: 81
Study 6143042 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated cold‐adapted reassortant influenza virus vaccine
Number of subjects: 81
Study 28843034 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (2 face-to-face and 5 telephone counselling sessions)
Number of subjects: 59
Study 28843034 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 59
Study 27752167 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOPE+L-asparaginase (L-ASP) regimen
Number of subjects: 61
Study 27752167 — intervention group
Group type: COMPARATOR
Intervention: CHOPE regimen
Number of subjects: 61
Study 27752167 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival rates in CHOPE+L
Number of subjects: 61
Study 27752167 — intervention group
Group type: COMPARATOR
Intervention: Overall survival rates in CHOPE
Number of subjects: 61
Study 24103693 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with social phobia (anxiety induced)
Number of subjects: 73
Study 24103693 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with social phobia (no anxiety induction)
Number of subjects: 73
Study 24103693 — intervention group
Group type: COMPARATOR
Intervention: Control children (anxiety induced)
Number of subjects: 73
Study 24103693 — intervention group
Group type: COMPARATOR
Intervention: Control children (no anxiety induction)
Number of subjects: 73
Study 24103693 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report measures of anxiety
Number of subjects: 73
Study 22041866 — intervention group
Group type: EXPERIMENTAL
Intervention: mIL‐11 (7.5 μg/kg/day) for 10 days, beginning 72 h after chemotherapy (cycle-1)
Number of subjects: 88
Study 22041866 — intervention group
Group type: COMPARATOR
Intervention: rhIL‐11 (25 μg/kg/day) for 10 days (cycle-2)
Number of subjects: 88
Study 22041866 — intervention group
Group type: EXPERIMENTAL
Intervention: mIL‐11
Number of subjects: 88
Study 22041866 — intervention group
Group type: COMPARATOR
Intervention: rhIL‐11
Number of subjects: 88
Study 22041866 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 88
Study 20215823 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (Group 1)
Number of subjects: 216
Study 20215823 — intervention group
Group type: COMPARATOR
Intervention: Control (Group 3)
Number of subjects: 216
Study 20215823 — intervention group
Group type: EXPERIMENTAL
Intervention: EPS-Antibiotics (Group 4)
Number of subjects: 216
Study 17661724 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (Aurene, 600 mg)
Number of subjects: 12
Study 17661724 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (Trileptal, 600 mg)
Number of subjects: 12
Study 16160416 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 ml hyperbaric bupivacaine (Marcaine Spinal Heavy 0.5%)
Number of subjects: 93
Study 16160416 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 ml hyperbaric bupivacaine (Marcaine Spinal Heavy 0.5%)
Number of subjects: 93
Study 16160416 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 ml hyperbaric bupivacaine (Marcaine Spinal Heavy 0.5%)
Number of subjects: 93
Study 12006922 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized, controlled trials published in 2000
Number of subjects: 17
Study 12006922 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized, controlled trials published in 1995
Number of subjects: 17
Study 12006922 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized, controlled trials published in 1990
Number of subjects: 17
Study 12006922 — intervention group
Group type: COMPARATOR
Intervention: Other journals evaluated (Annals of Surgery, Archives of Surgery, Gastroenterology)
Number of subjects: 17
Study 12006922 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical power calculations
Number of subjects: 17
Study 10630264 — intervention group
Group type: EXPERIMENTAL
Intervention: Poisoning-related visits to emergency departments
Number of subjects: 100000000
Study 10630264 — intervention group
Group type: EXPERIMENTAL
Intervention: Poisoning-related visits
Number of subjects: 100000000
Study 10630264 — intervention group
Group type: COMPARATOR
Intervention: Illness visits
Number of subjects: 100000000
Study 10630264 — intervention group
Group type: COMPARATOR
Intervention: Nonpoisoning-related injury visits
Number of subjects: 100000000
Study 8562661 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplantation of human fetal mesencephalic tissue
Number of subjects: 9
Study 1824143 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate, 1 g 4 times a day (Group 1)
Number of subjects: 79
Study 1824143 — intervention group
Group type: COMPARATOR
Intervention: Famotidine, 40 mg single evening dose (Group 2)
Number of subjects: 79
Study 6242957 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam 20 mg once daily
Number of subjects: 60
Study 6242957 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 250 mg bid
Number of subjects: 60
Study 6242957 — intervention group
Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 60
Study 30985539 — intervention group
Group type: EXPERIMENTAL
Intervention: Active warming group (n=25)
Number of subjects: 50
Study 30985539 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=25)
Number of subjects: 50
Study 29601316 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazoxide (200-400 mg daily, twice a day)
Number of subjects: 6
Study 29601316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 25771490 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin (5 mg/d)
Number of subjects: 44
Study 24725805 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral α‐methyl‐para‐tyrosine (AMPT)
Number of subjects: 27
Study 24725805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 22295812 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of acupuncture and medicine (heat-producing needling at Pishu (BL 20) and Zhishi (BL 52) with Terazosin Hydrochloride, Bisoprolol Fumarate tablets, or compound Reserpinum Triamterene tablet for high blood pressure)
Number of subjects: 240
Study 22295812 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicine group I (Renin‐Angiotensin‐Aldosterone system interruption with Benazepril Hydrochloride and Telmisartan for blood pressure control)
Number of subjects: 240
Study 22295812 — intervention group
Group type: COMPARATOR
Intervention: Medicine group II (placebo with same medicine therapy as combined therapy for high blood pressure)
Number of subjects: 240
Study 21269039 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% triclosan/2.0% PVM/MA copolymer/0.243% sodium fluoride dentifrice
Number of subjects: 171
Study 21269039 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.454% stannous fluoride, sodium hexametaphosphate, and zinc lactate dentifrice
Number of subjects: 171
Study 21269039 — intervention group
Group type: COMPARATOR
Intervention: 0.243% sodium fluoride dentifrice
Number of subjects: 171
Study 17703390 — intervention group
Group type: COMPARATOR
Intervention: Propofol alone (Group A)
Number of subjects: 199
Study 17703390 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedato-analgesic cocktail (midazolam, ketamine, pentazocine plus propofol) (Group B)
Number of subjects: 199
Study 15640455 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular meal pattern (6 occasions/d)
Number of subjects: 10
Study 12394941 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g of human serum albumin every 8 hrs with continuous infusion furosemide
Number of subjects: 37
Study 12394941 — intervention group
Group type: COMPARATOR
Intervention: Dual placebo
Number of subjects: 37
Study 10337446 — intervention group
Group type: EXPERIMENTAL
Intervention: St. John's wort extract LoHyp-57 (800 mg daily)
Number of subjects: 149
Study 10337446 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (20 mg daily)
Number of subjects: 149
Study 10337446 — intervention group
Group type: EXPERIMENTAL
Intervention: St. John's wort extract LoHyp-57
Number of subjects: 149
Study 10337446 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 149
Study 7856515 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid aerosol (10 microM MMAD H2SO4, pH 2.0, 500 micrograms/m3)
Number of subjects: 7
Study 7856515 — intervention group
Group type: COMPARATOR
Intervention: Control aerosol (equiosmolar NaCl)
Number of subjects: 7
Study 1780996 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (100 micrograms/kg, single dose)
Number of subjects: 71
Study 1780996 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC) (3 mg/kg for one day, then 6 mg/kg daily for 12 d)
Number of subjects: 71
Study 1780996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 7174860 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (40 mg)
Number of subjects: 81
Study 7174860 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (60 mg)
Number of subjects: 81
Study 7174860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 30306731 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-gene signature (CTSW, PCSK4, LRRC8D, TNFRSF18, IHH, and CDKN2A) developed using multivariate Cox proportional hazard regression.
Number of subjects: 0
Study 29178717 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacement of brush head every 4 weeks (R)
Number of subjects: 49
Study 29178717 — intervention group
Group type: COMPARATOR
Intervention: Non-replacement of brush head over 6 months (NR)
Number of subjects: 49
Study 29178717 — intervention group
Group type: COMPARATOR
Intervention: Sonic action toothbrushes in NR group
Number of subjects: 49
Study 24485398 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride 4 mg
Number of subjects: 43
Study 24485398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 21895786 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermasilk® briefs
Number of subjects: 96
Study 21895786 — intervention group
Group type: COMPARATOR
Intervention: Cotton placebo briefs
Number of subjects: 96
Study 20300631 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine HIV-1 viral load (VL) monitoring at ART-initiation and at 3, 6, 12, and 18 months
Number of subjects: 1973
Study 20300631 — intervention group
Group type: COMPARATOR
Intervention: Local standard of care (immunological and clinical criteria for treatment failure, discretionary VL testing)
Number of subjects: 1973
Study 17595353 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 49
Study 17595353 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 49
Study 16371798 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 52
Study 16371798 — intervention group
Group type: COMPARATOR
Intervention: Sodium hyaluronate
Number of subjects: 52
Study 11926713 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 8.75 mg lozenge
Number of subjects: 0
Study 11926713 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 8.75 mg lozenge with concomitant antibiotics
Number of subjects: 0
Study 11926713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9807204 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 360
Study 9807204 — intervention group
Group type: COMPARATOR
Intervention: Control (no radiotherapy)
Number of subjects: 360
Study 8082521 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultralente insulin (Humulin U)
Number of subjects: 16
Study 8082521 — intervention group
Group type: COMPARATOR
Intervention: Intermediate insulin (Humulin I)
Number of subjects: 16
Study 2554837 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 15 mg/day (beta-blocker)
Number of subjects: 8
Study 2554837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30596812 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel/carboplatin/cetuximab (PCC)
Number of subjects: 136
Study 30596812 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel/cisplatin/5-fluorouracil/cetuximab (C-TPF)
Number of subjects: 136
Study 30596812 — intervention group
Group type: COMPARATOR
Intervention: Historical control from RTOG-0129
Number of subjects: 136
Study 27055279 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin infusion (0.26 μg/kg/h)
Number of subjects: 13
Study 27055279 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin infusion (2.0 μg/kg/h)
Number of subjects: 13
Study 27055279 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 13
Study 25151916 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (PE plus sertraline)
Number of subjects: 642
Study 25151916 — intervention group
Group type: COMPARATOR
Intervention: Prolonged exposure (PE)
Number of subjects: 642
Study 22510805 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous-intensity walking program (70% HRR)
Number of subjects: 44
Study 22510805 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity walking program (30% HRR)
Number of subjects: 44
Study 22510805 — intervention group
Group type: COMPARATOR
Intervention: Both groups (LI and VI)
Number of subjects: 44
Study 20348496 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg primaquine daily for 7 days
Number of subjects: 85
Study 20348496 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg primaquine daily for 7 days
Number of subjects: 85
Study 20348496 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 85
Study 18053592 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (n=44)
Number of subjects: 74
Study 18053592 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=30)
Number of subjects: 74
Study 17111584 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidetector helical computed tomography (MDCT)
Number of subjects: 23
Study 17111584 — intervention group
Group type: COMPARATOR
Intervention: Chest radiography (CXR)
Number of subjects: 23
Study 12820784 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta‐1a
Number of subjects: 274
Study 12820784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 274
Study 11763946 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma arc curing (P)
Number of subjects: 16
Study 11763946 — intervention group
Group type: COMPARATOR
Intervention: Halogen light curing (H)
Number of subjects: 16
Study 9011483 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 MU interferon (IFN)-alpha2b three times a week for six months
Number of subjects: 230
Study 9011483 — intervention group
Group type: COMPARATOR
Intervention: 3 MU interferon (IFN)-alpha2b three times a week for six months
Number of subjects: 230
Study 9011483 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 MU interferon (IFN)-alpha2b three times a week for two years
Number of subjects: 230
Study 9011483 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 230
Study 9011483 — intervention group
Group type: EXPERIMENTAL
Intervention: Two years of IFN therapy
Number of subjects: 230
Study 9011483 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing IFN therapy for at least 12 months
Number of subjects: 230
Study 9011483 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial IFN treatment courses of 24 months
Number of subjects: 230
Study 7961557 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine concentration > 420 ng/mL
Number of subjects: 58
Study 7961557 — intervention group
Group type: COMPARATOR
Intervention: Clozapine concentration < 420 ng/mL
Number of subjects: 58
Study 7961557 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine concentration > 420 ng/mL at Week 12
Number of subjects: 58
Study 7961557 — intervention group
Group type: COMPARATOR
Intervention: Clozapine concentration < 420 ng/mL at Week 12
Number of subjects: 58
Study 2965438 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month interval worming with levamisole
Number of subjects: 50
Study 2965438 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month interval worming with levamisole
Number of subjects: 50
Study 29873009 — intervention group
Group type: EXPERIMENTAL
Intervention: TAF/TIM
Number of subjects: 115
Study 29873009 — intervention group
Group type: COMPARATOR
Intervention: LAT/TIM
Number of subjects: 115
Study 28319109 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole food plant-based (WFPB) diet with vitamin B12 supplementation
Number of subjects: 65
Study 28319109 — intervention group
Group type: COMPARATOR
Intervention: Normal care (control)
Number of subjects: 65
Study 26771267 — intervention group
Group type: EXPERIMENTAL
Intervention: IV dexamethasone (0.5 mg/kg in 5 mL saline)
Number of subjects: 60
Study 26771267 — intervention group
Group type: COMPARATOR
Intervention: Control (5 mL IV saline)
Number of subjects: 60
Study 23570591 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance (U group, n = 30)
Number of subjects: 60
Study 23570591 — intervention group
Group type: COMPARATOR
Intervention: Nerve stimulation (N group, n = 30)
Number of subjects: 60
Study 21755811 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (dorzolamide 20 mg/ml + timolol 5 mg/ml eye drops)
Number of subjects: 38